colorbar
Get convenient and comprehensive reimbursement support
SUSTOL Connect and patient support
SUSTOL Practice Support
Other SUSTOL Connect
programs and services

Stand by SUSTOL Program*

  • Heron Therapeutics is committed to ensuring that patients have coverage when SUSTOL is administered. This program helps mitigate the economic burden of denials
  • In the event of a qualifying coverage denial, the Stand by SUSTOL Program will credit your practice for the cost of SUSTOL

Insurance Verification

  • Provides patient-specific insurance eligibility and coverage information, including benefits for medical plan coverage based on the patient’s benefit design

Prior Authorization (PA) Support

  • Assists with PA requests by:
    • Furnishing information concerning the payer’s PA requirements, and/or
    • Sending PA form or template letter of medical necessity to the physician for completion (if available)
    • Monitoring the status of the requests

Appeals

  • Reimbursement Counselors will provide information to the practice in connection with an appeal
  • SUSTOL Connect™ will contact the payer to:
    • Determine the reason for the denial
    • Obtain information related to appeal requirements
    • Provide the practice with information on how to submit the appeal, and
    • Monitor the status of the request

Billing and Coding Support

  • Billing and coding support for practices that may not have specific experience billing for SUSTOL (ie, billing, coding, or claims submission inquiries)
  • Reimbursement Counselors may provide tools such as letters, statements, and sample claims forms as needed

Drug Replacement

  • In the event that SUSTOL arrives damaged, is otherwise determined to be unfit for patient use, or has expired, Heron Therapeutics, Inc., will credit your practice for the purchase price of the product
  • Contact Heron Connect at 1-844-HERON11 (1-844-437-6611). Hours of operation are Monday–Friday, 8 am–8 pm ET
* The Stand by SUSTOL Program and the other product support programs offered by Heron Therapeutics do not impose any purchase obligation at any time or in any manner. Use of SUSTOL may be discontinued at any time, without penalty.
A qualifying reimbursement denial occurs when, for patients covered under commercial insurance: (a) the verification of benefits and satisfaction of all payer conditions for reimbursement is completed, (b) the patient’s treatment with the drug is nonetheless denied coverage, and, (c) after an appeals process has been followed, coverage is still denied. Government-insured patients are not eligible for the program.
Determination will be made by the manufacturer of SUSTOL.
Contact SUSTOL Connect™

    For information on how to access SUSTOL, call 1-855-SUSTOL-6 (1-855-787-8656), 8 am to 8 pm ET, Monday through Friday.

    To benefit from programs offered by SUSTOL Connect™, a completed patient program enrollment form should be submitted by fax to 1-844-504-8652, and in most cases, results will be provided within 2 business days.

Practice Resources
SUSTOL patient copay assistance program registration form
Patient Copay Assistance Program Registration Form
A form used to enroll individual patients solely into the SUSTOL Copay Assistance Program. The one-time Copay Assistance Program Practice Enrollment Form must also be completed.

 

SUSTOL copay assistance program practice enrollment form
SUSTOL Copay Assistance Program Practice Enrollment Form
A one-time form your practice must complete in order to participate in the simplified Copay Assistance Registration process.

Indication

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Important Safety Information

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

For more information about SUSTOL, please see full Prescribing Information.





Indication

SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Important Safety Information

Contraindications

SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or any other 5-HT3 receptor antagonist.

Warnings and Precautions

Injection site reactions (ISRs), including infection, bleeding, pain and tenderness, nodules, swelling, and induration, have occurred with SUSTOL. Monitor for ISRs following SUSTOL injection. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. In patients receiving antiplatelet agents or anticoagulants, consider the increased risk of bruising or severe hematoma prior to the use of SUSTOL.

Monitor for constipation and decreased bowel activity and consider optimizing patients’ current bowel regimens used for managing preexisting constipation. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur.

Hypersensitivity reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve.

Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.

Use in Specific Populations

Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days.

Adverse Reactions

Most common adverse reactions (≥3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux.

For more information about SUSTOL, please see full Prescribing Information.